ArticleNeurology2019
Leptomeningeal metastases in glioma: The Memorial Sloan Kettering Cancer Center experience.
Article in Neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 4 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Surgical outcomes in diffuse leptomeningeal glioneuronal tumours: a systematic review and individual patient data meta-analysis.Neurosurgical review · 2025Pooled it
- Ten Years of VASARI Glioma Features: Systematic Review and Meta-Analysis of Their Impact and Performance.AJNR. American journal of neuroradiology · 2024Pooled it
- Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: a systematic review.Journal of neuro-oncology · 2024Pooled it
- Leptomeningeal disease in glioblastoma: endgame or opportunity?Journal of neuro-oncology · 2021Pooled it
- Role of CSF interleukin-6 in the prognosis of patients with Leptomeningeal metastases of glioblastoma.Discover oncology · 2026Article
- Article
- Leptomeningeal Dissemination in TERT Promoter-mutant Anaplastic Pleomorphic Xanthoastrocytoma Responding to BRAF-MEK Inhibition: A Case Report.NMC case report journal · 2026Article
- Is leptomeningeal dissemination in oligodendroglioma predictable? Evidence from a scoping review.Frontiers in oncology · 2026Review
- Spinal Metastasis from Supratentorial Glioblastoma: A Registry-Based Case Series and a Review of the Literature.Cancers · 2025Article
- Leptomeningeal metastases at recurrence in IDH-wildtype glioblastomas: incidence, risk factors, and prognosis based on postcontrast FLAIR imaging.European radiology · 2025Article
- Rapid response to BRAF/MEK inhibitor therapy within 2 weeks for high-grade glioma with leptomeningeal metastasis: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Spinal cord metastasis in a long-term survivor of primary malignant glioblastoma: A case report.Oncology letters · 2025Article
- Molecular profile of adult primary leptomeningeal gliomatosis aligns with glioblastoma, IDH-wildtype.Brain pathology (Zurich, Switzerland) · 2025Article
- Diagnostic Performance of Fast Brain MRI Compared with Routine Clinical MRI in Patients with Glioma Grades 3 and 4: A Pilot Study.AJNR. American journal of neuroradiology · 2025Article
- Primary diffuse leptomeningeal glioblastoma: a case report and literature review.Journal of neuro-oncology · 2025Review
- Article
- Clinical Reasoning: A 63-Year-Old Man With Progressive Multicranial Neuropathy and Leptomeningeal Enhancement.Neurology · 2024Article
- Article
- Successful treatment of pediatric patients with high-grade gliomas featuring leptomeningeal metastases by targeting BRAF V600E mutations with dabrafenib plus trametinib: two illustrative cases.International cancer conference journal · 2024Article
- Recurrent Pleomorphic Xanthoastrocytoma Presenting With Diffuse Leptomeningeal Spread.The Neurohospitalist · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo perform a retrospective analysis examining the incidence and prognosis of glioma patients with leptomeningeal disease (LMD) at Memorial Sloan Kettering Cancer Center over a 15-year period and correlate these findings with clinicopathologic characteristics.
methodsWe conducted a retrospective review of glioma patients with LMD at Memorial Sloan Kettering Cancer Center diagnosed from 2001 to 2016. Patients were identified through a keyword search of their electronic medical record and by ICD-9 codes.
resultsOne hundred three patients were identified with disseminated LMD and 85 patients with subependymal spread of disease, 4.7% of all patients with glioma. These cohorts were analyzed separately for time to development of disseminated LMD/subependymal LMD, median overall survival, and survival from LMD diagnosis. Patients were pooled for subsequent analyses (n = 188) because of comparable clinical behavior. LMD was present at glioma diagnosis in 10% of patients. In the remaining 90% of patients diagnosed at recurrence, time to LMD diagnosis, survival after LMD diagnosis, and overall survival varied by original histology. Patients with oligodendroglioma had a median survival of 10.8 (range 1.8-67.7) months, astrocytoma 6.5 (0.1-28.5) months, and glioblastoma 3.8 (0.1-32.6) months after LMD diagnosis. In addition, we found that treatment of LMD was associated with superior performance status and increased survival.
conclusionPatients with LMD diagnosed at relapse may not have decreased overall survival as compared to historical controls with parenchymal relapse and may benefit from treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.